Asthma–COPD overlap syndrome (ACOS) vs 'pure' COPD: a distinct phenotype?. Issue 1 (27th September 2016)

• Record Type: Journal Article
• Authors: Caillaud, D.; Chanez, P.; Escamilla, R.; Burgel, P‐R.; Court‐Fortune, I.; Nesme‐Meyer, P.; Deslee, G.; Perez, T.; Paillasseur, J‐L.; Pinet, C.; Jebrak, G.; Roche, N.
• Other Names: Bourdin A. investigator.; Brinchault‐Rabin G. investigator.; Carré P. investigator.; Zysman M. investigator.; Deslée G. investigator.
• Is Part Of: Allergy. Volume 72:Issue 1(2017:Jan.)
• Page Start: 137
• Page End: 145
• Publication Date: 2016-09-27
• Subjects: Asthma‐COPD overlap syndrome (ACOS) -- asthma‐COPD overlap syndrome -- chronic obstructive pulmonary disease (COPD) -- mortality -- severity -- treatment; Allergy -- Periodicals; 616.97
• DOI: 10.1111/all.13004
• Languages: English
• ISSNs: 0105-4538

Abstract

Abstract: Background: Some studies suggest that asthma–COPD overlap syndrome (ACOS) is associated with worse outcomes than chronic obstructive pulmonary disease (COPD). The goal of this study was to further explore the clinical characteristics and survival of patients with ACOS identified in a real‐life cohort of patients with COPD. Methods: Data from the French COPD cohort 'INITIATIVES BronchoPneumopathie Chronique Obstructive' ( n = 998 patients) were analyzed to assess the frequency of ACOS defined as a physician diagnosis of asthma before the age of 40 years and to analyze its impact. Univariate analyses were performed to assess the relationship between ACOS and sociodemographic characteristics, risk factors (smoking, occupational exposure, atopic diseases), symptoms (chronic bronchitis, dyspnea‐modified Medical Research Council scale and baseline dyspnea index), quality of life (QoL), mood disorders, exacerbations, comorbidities, lung function, prescribed treatment, and survival. Results: ACOS was diagnosed in 129 patients (13%). In multivariate analyses, ACOS was associated negatively with cumulative smoking (odds ratio [OR]: 0.992; 95% CI 0.984–1.000 per pack‐year) and positively with obesity: OR: 1.97 [1.22–3.16], history of atopic disease (hay fever: OR: 5.50 [3.42–9.00] and atopic dermatitis: OR 3.76 [2.14–6.61]), and drug use (LABA + ICS: 1.86 [1.27–2.74], antileukotrienes 4.83 [1.63–14.34], theophylline: 2.46 [1.23–4.91], and oral corticosteroids: [2.99;.1.26–7.08]). No independent association was found with dyspnea, QoL, exacerbations, and mortality. Conclusions: Compared to 'pure' COPD patients, patients with ACOS exhibit lower cumulative smoking, suffer more from obesity and atopic diseases, and use more asthma treatments. Disease severity (dyspnea, QoL, exacerbations, comorbidities) and prognosis (mortality) are not different from 'pure' COPD patients.